Although biomarkers are not widely accepted as important clinical tools, they contribute valuable information for the management of patients with HCC, with regards to surveillance, diagnosis, evaluation of treatment efficacy, and prediction of outcomes Comparing the levels of clinical pathological markers, such as AFP, AST, and ALT, which partially reflects the body function and nutrition status, no significant difference between the wild-type and polymorphic genotypes of each SERPINB5 SNPs in HCC patients was observed (Table S2). The gene discussed is AFP; the disease is hepatocellular carcinoma.